BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35284050)

  • 1. Understanding the influence of AMG 510 on the structure of KRAS
    Li Y; Han L; Zhang Z
    Comput Struct Biotechnol J; 2022; 20():1056-1067. PubMed ID: 35284050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations.
    Pantsar T
    Sci Rep; 2020 Jul; 10(1):11992. PubMed ID: 32686745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
    Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
    Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Tu G; Liu Q; Qiu Y; Leung EL; Yao X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition.
    Huynh MV; Parsonage D; Forshaw TE; Chirasani VR; Hobbs GA; Wu H; Lee J; Furdui CM; Poole LB; Campbell SL
    J Biol Chem; 2022 Aug; 298(8):102186. PubMed ID: 35753348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling receptor flexibility in the structure-based design of KRAS
    Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
    J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.
    Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M
    Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research.
    Wu LL; Jiang WM; Liu ZY; Zhang YY; Qian JY; Liu Y; Huang YY; Li K; Li ZX; Ma GW; Xie D
    Discov Oncol; 2023 Jun; 14(1):91. PubMed ID: 37284902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS
    Luo L; Zheng T; Wang Q; Liao Y; Zheng X; Zhong A; Huang Z; Luo H
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
    Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
    ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Breakthrough Brought about by Targeting KRAS
    Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS
    Zhuang H; Fan J; Li M; Zhang H; Yang X; Lin L; Lu S; Wang Q; Liu Y
    Front Oncol; 2022; 12():915512. PubMed ID: 36033504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on Sotorasib (AMG 510) for
    Zhang SS; Nagasaka M
    Lung Cancer (Auckl); 2021; 12():115-122. PubMed ID: 34675734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL.
    Kitazawa M; Miyagawa Y; Koyama M; Nakamura S; Hondo N; Miyazaki S; Muranaka F; Tokumaru S; Yamamoto Y; Ehara T; Kuroiwa M; Tanaka H; Komatsu D; Takeoka M; Soejima Y
    Mol Clin Oncol; 2021 Jul; 15(1):148. PubMed ID: 34094546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
    Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
    Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors.
    Davies CW; Oh AJ; Mroue R; Steffek M; Bruning JM; Xiao Y; Feng S; Jayakar S; Chan E; Arumugam V; Uribe SC; Drummond J; Frommlet A; Lu C; Franke Y; Merchant M; Koeppen H; Quinn JG; Malhotra S; Do S; Gazzard L; Purkey HE; Rudolph J; Mulvihill MM; Koerber JT; Wang W; Evangelista M
    Nat Biotechnol; 2022 May; 40(5):769-778. PubMed ID: 34992247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.